ArticleSignal transduction and targeted therapy2025

Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma.

Qi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.